As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

"Madagascar’s HIV epidemic is being fueled by gaps in prevention and glaring inequalities, which urgently need to be ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Health NGO, Right to Care, highlights the urgent need for circumcision among boys aged 15 and older in KwaZulu-Natal to ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

It continues to maintain its dominant position with an increasing market share for treatment and prevention. Gilead projects HIV sales to grow 4% in 2024. Lenacapavir is already approved under the ...

Data reinforce that twice-yearly lenacapavir could be a highly effective and potentially game-changing HIV prevention option. The double-blind, multicenter, randomized study phase III study ...